An observational study in Hemoptysis, Haemoptysis and Lung Disease, sponsored by Université de Sherbrooke. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-23.
Sponsored by Université de Sherbrooke · Observational
The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.
RATIONALE:
Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is different depending on the causes, which are not well defined for the North American population. Despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the North-American population. Tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center.
Also, there are no known official guidelines regarding the investigation and management of hemoptysis. The investigators hypothesized that the use of modern technology in a North American population may result in different findings and provide a more accurate diagnostic approach.
Therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a North-American tertiary center.
METHOD:
The investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. Each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. All-cause mortality at 2 years was also recorded.
Descriptive statistical analyses will conducted on the data available.
37 studies on the registry are indexed under Hemoptysis; 6 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 176 across 15 observational studies indexed under Hemoptysis.
Browse Hemoptysis studies →Université de Sherbrooke is the lead sponsor of 295 studies on the registry; 65 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Any patient presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke on an outpatient basis, emergency department or hospitalized at hopital Fleurimont or Hotel-Dieu of Sherbrooke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any patient over the age of 18 presenting with:
Exclusion Criteria:
Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
Etiologies of hemoptysis
Defining the prevalence of pulmonary diseases by measuring the percentage of patients presenting with hemoptysis caused by lung cancer, bronchiectasis, pulmonary embolism, arteriovenous fistula, pneumonia, bronchitis, tuberculosis, mycosis, heart failure, pseudohemoptysis, cryptogenic and other causes.
Time frame: 5 years
Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography.
Determining the sensitivity in obtaining the etiology of the hemoptysis episode of each diagnostic modality that follows : chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography in the diagnosis of different etiologies of hemoptysis.
Time frame: 5 years
All-cause mortality at 2 years
All-cause mortality at 2 years after the diagnosis of hemoptysis.
Time frame: 2 years
Smoking status
Determining the percentage of patients who : never smoked, is an active smoker, former smoker or unknown status.
Time frame: Day 1
Age
Determining the average age of the enrolled patients.
Time frame: Day 1
Gender
Determining the percentage of each gender of the enrolled patients.
Time frame: Day 1
International Normalized Ratio
Determining the median of the international normalized ratio (INR).
Time frame: Day 1
Partial Thromboplastin Time
Determining the median of the partial thromboplastin time (PTT).
Time frame: Day 1
Platelet count
Determining the average of the platelet count measured per microliter of blood.
Time frame: Day 1
Plan to share: Undecided
This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.